ArticleIJU case reports2026
Malignant/Sarcomatous Transformation of Mixed Epithelial and Stromal Tumor of the Kidney: A Case Report.
Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Malignant transformation of mixed epithelial and stromal tumors of the kidney (MESTK) is extremely rare. Case Presentation: A 39-year-old man with gross hematuria was suspected to have renal cell carcinoma, measuring 13 cm in diameter. No distant metastases were observed. The patient underwent laparoscopic left nephrectomy. Histopathological examination revealed malignant sarcomatous transformation of MESTK. Immunohistochemically, the tumor was positive for PAX8, CD10, and desmin, as well as for estrogen, progesterone, and androgen receptors. Comprehensive genomic profiling did not yield any treatment recommendations or relevant information. The patient will be closely monitored for any signs of recurrence or metastasis. Conclusion: The associated prognosis for patients with nonmetastatic MESTKs exhibiting malignant transformation is unknown; however, strict follow-up is recommended due to the histological grade of malignancy and local invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.